Posted on December 1, 2021 by Sitemaster
In late October, we had commented on the then-latest revision of the National Comprehensive Cancer Network (NCCN)’s guidelines on the initial management of men with low-risk forms of localized prostate cancer. Specifically we had protested the removal of any suggestion that this form of prostate cancer should — preferably — be managed using active surveillance. The NCCN has now released a new revision to the guidelines that has modified the prior suggestion. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, guidelines, low-risk, NCCN, surveillance | 4 Comments »
Posted on November 30, 2021 by Sitemaster
About 100 patients, clinicians, and others are already registered as attendees at the conference on
Click on the link above for more information and to register. There is still plenty of time to join us.
The conference will take place from 12:00 pm to 4:00 pm Eastern time on Monday, December 13 AND on 12:00 pm to 4:00 pm on Thursday, December 16.
Continue reading →
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Uncategorized | Leave a comment »
Posted on October 20, 2021 by Sitemaster
As many readers will already be aware, the National Comprehensive Cancer Network (NCCN) has recently removed the word “preferred” from its statement regarding the use of active surveillance (AS) as an appropriate form of management of men with low-risk forms of localized prostate cancer. A broad swath of specialists in the initial management of low-risk disease, as well as many in the patient advocacy community, have been highly critical of this change to the NCCN guidelines. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active, guidelines, low-risk, NCCN, surveillance | 10 Comments »
Posted on August 19, 2021 by Sitemaster
The decision about whether or not to treat the entire pelvic lymph node area along with the prostate (called whole pelvic radiation therapy or WPRT) or to treat just the prostate with a margin around it (called prostate-only radiation therapy or PORT) has long been a matter of judgment. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pelvic, prostate-only, radiation, risk | 9 Comments »
Posted on August 12, 2021 by Sitemaster
For many years your sitemaster has been advising patients that overly early use of androgen deprivation therapy (ADT) in many men with progressive prostate cancer is not necessarily the best decision (for a number of possible reasons). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, initiation, metastasis., timing | 9 Comments »
Posted on August 11, 2021 by Sitemaster
In 2016, we looked at the Candiolo risk stratification system for radiation therapy. To our knowledge, it has not been prospectively validated or widely adopted. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: nomogram. radiation, predictive, prognosis, risk, stratification, therapy | 4 Comments »
Posted on July 26, 2021 by Sitemaster
As of Friday (July 22), we had received more than 250 responses to our brief survey on research into active surveillance. Most of these are from patients and some from their familial supporters (spouses, partners, etc.). However,we are still interested in getting more input — especially from clinicians, including specialists, generalists, and allied health personnel like urology nurses! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, AS, research | 2 Comments »
Posted on July 26, 2021 by Sitemaster
Three more upcoming webinars this week will deal with (a) the work-up of men with prostate cancer prostate cancer who progress after first-line therapy (such as surgery, radiation, etc.); (b) whether Gleason 6 disease should really be defined as “prostate cancer”; and (c) an update on the most current information related to the evaluation and management of men with prostate cancer appropriate for active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: progression. active, surveillance, webinar | Leave a comment »
Posted on June 23, 2021 by Sitemaster
Three upcoming webinars deal with (a) the diagnosis and work-up of clinically significant forms of localized prostate cancer; (b) handling anxiety and related issues for men on active surveillance (AS); and (c) whether AS is appropriate for African Americans and others of African ethnicity. See below for details. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: education, patient, webinar | 1 Comment »
Posted on June 22, 2021 by Sitemaster
A diverse group of patients, patient advocates, patient spouses/supporters, physicians, and other researchers has come together, with funding support from the Patient Centered Outcomes Research Institute (PCORI), to plan a virtual conference for the fall of 2021. At that conference, we intend to discuss and identify new and evolving opportunities for research into the most appropriate, high-need, high-impact topics affecting the use of active surveillance (AS) for the management of favorable-risk forms of prostate cancer (i.e., low-risk and “favorable” intermediate-risk disease). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, research, surveillance | 5 Comments »
Posted on June 5, 2021 by Sitemaster
As we’ve seen, brachy boost therapy seems to have the best oncological results for men with very high-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: ADT, brachy boost, high-risk, hormonal therapy, radiotherapy | 1 Comment »
Posted on May 31, 2021 by Sitemaster
In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: imaging, PET scan, PyL, Pylarify | 16 Comments »
Posted on April 1, 2021 by Sitemaster
According to a recent article in Modern Pathology, a team of researchers at Yale University and at Memorial Sloan-Kettering Cancer Center (MSKCC) have been able to show that an artificial intelligence (AI) system designed and validated at MSKCC could be used to diagnose prostate cancer as either “suspicious” or “not suspicious” based on data from nearly 2,000 slides of prostate tissue acquired at Yale Medicine. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: AI, artificial, biopsy, intelligence, pathology, slide | 4 Comments »
Posted on March 22, 2021 by Sitemaster
As some of our readers will already be aware, Prostate Cancer International has been working in concert with Dr. M. Mihaj Siddiqui at the University of Maryland School of Medicine and the PATIENTS program at the University of Maryland School of Pharmacy to put together a grant request for funding for a program to identify evidence gaps to guide future research on the use of active surveillance to monitor low-risk prostate cancers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, initiative, research, surveillance | 3 Comments »
Posted on March 22, 2021 by Sitemaster
As Howard Wolinsky has been learning over the past few years, not all prostate cancer support groups are “equal” — in the sense that individual support group leaders may be seriously biased by their own personal experiences (which may have occurred many years ago). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: bias, group, support | 2 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 